- Conditions
- Immunoglobulin A (IgA) Nephropathy
- Interventions
- PS-002
- Genetic
- Lead sponsor
- Purespring Therapeutics Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 3
- States / cities
- Miami, Florida • Baltimore, Maryland • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced May 21, 2026, 7:16 PM EDT